Rein Therapeutics Inc(RNTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
October 7 at 4:00 PM ET (Korea 10/8 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.72 | Insider Own | 8.49% | Shs Outstand | 85.8M | Perf Week | -1.9% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | -1.09% | Insider Trans | 0.99% | Shs Float | 79.0M | Perf Month | -8.56% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | -0.1 | Inst Own | 48.7% | Short Float | 0.85% | Perf Quarter | -20.96% |
| Income | -0.05B | P/S | - | EPS this Y | 76.53% | Inst Trans | 44.37% | Short Ratio | 1.58 | Perf Half Y | -49.76% |
| Sales | 0.00B | P/B | 6.63 | EPS next 5Y | 32.79% | ROA | -80.62% | Short Interest | 0.67M | Perf YTD | -32.01% |
| Book/sh | 0.12 | P/C | 1.67 | EPS past 3/5Y | 31.21% 30.56% | ROE | -96.42% | 52W High | -63.82% ($2.18) | Perf Year | -45.23% |
| Cash/sh | 0.47 | P/FCF | - | Sales past 3/5Y | - | ROIC | -90.14% | 52W Low | 13.65% ($0.69) | Perf 3Y | -44.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 36.23% | Gross Margin | - | Volatility(W/M) | 9.6% 8.97% | Perf 5Y | -96.05% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.27 | EPS Q/Q | 66.32% | Profit Margin | - | RSI (14) | 49.26 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.27 | Sales Q/Q | - | SMA20 | 1.02% ($0.78) | Beta | 1.46 | Target Price | $6 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/14 | SMA50 | 0.15% ($0.79) | Rel Volume | 1.05 | Prev Close | $0.82 |
| Employees | 10 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 41.18% - | SMA200 | -27.43% ($1.09) | Avg Volume(3M) | 0.42M | Price | $0.79 |
| IPO | 2017/6/29 | Option/Short | No/Yes | Trades | 760 | Volume | 446,972 | Change | -4.4% |
A clinical-stage biopharmaceutical company developing novel drug candidates targeting rare lung diseases and fibrotic conditions. Headquartered in the United States, it is classified as a micro-cap biotech operating with a research-and-development focus, with no commercialized products yet. Pipeline progress serves as the central variable driving the company's valuation.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded about as much as usual That is 105% of its average volume.
RNTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +76.5% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.0%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 48.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #399 of 592 in the industry
Based on market cap of $68M.
SPRO#398 Spero Therapeutics Inc $68M PER 10.7 RNTX#399 Rein Therapeutics Inc $68M PER - 
FBIO#399 Fortress Biotech Inc $68M PER 0.8 
CSBR#401 Champions Oncology Inc $68M PER - 
XBIT#402 XBiotech Inc $67M PER - 
FAQ
What kind of company is RNTX?
RNTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RNTX?
The market cap of RNTX is approximately $68M, ranking 4,769 within its sector.
What is the 52-week high and low for RNTX?
RNTX has recorded a 52-week high of $2.18 and a low of $0.69.
